CI

At a glance

ClinicalIndex Comparison Record
Phase 4Completed· 103 enrolled
Drug / intervention
Lactobacillus rhamnosus GGdietary
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01551186
NCT01551186Phase 4Completed
CompareCT.gov

The Use of the Probiotic, Lactobacillus Rhamnosus GG to Evaluate Colonization With Antimicrobial Resistant Bacteria in High Risk Patients

Washington University School of Medicine·interventional·Posted Mar 12, 2012·Updated Dec 17, 2018

In Brief

A Phase 4 clinical trial evaluating Lactobacillus rhamnosus GG for Infectious Disease of Digestive Tract. Completed, enrolled 103 participants across 1 site.

Detailed Summary

The purpose of this study is to evaluate the effectiveness of bacteria called Lactobacillus GG, a Probiotic, in preventing the growth of resistant bacteria in the digestive tract in patients on a ventilator.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsInfectious Disease of Digestive Tract
CountriesUnited States
CollaboratorsCenters for Disease Control and Prevention

Timeline

Phase 4CompletedFinished
201220132014201520162017201820192020202120222023202420252026
First PostedMar 12, 2012
Enrollment StartFeb 1, 2012
Primary CompletionDec 1, 2013
TodayJul 2, 2026
Enrollment to primary: 1.8 yearsPosted 14.3 years ago

Interventions

Lactobacillus rhamnosus GGdietary

1 capsule containing 10 billion cells of Lactobacillus rhamnosus GG on a twice-daily basis